9/27/2023 0 Comments Netspot neuroendocrineBetter diagnosticsĬombined with more awareness and education (including the important pathologists ), more NETs than ever are being found, and many found earlier. To sum that up – Neuroendocrine Cancer is also a growth industry. Another piece of good news is that the increase in Neuroendocrine Cancer incidence is also due to earlier diagnosis. This has led to a revised set of epidemiological information in many countries that have made the effort to accurately update their cancer registries and there are consistent reports of incidence rates way beyond the recognised rare thresholds. So how does this affect Neuroendocrine Cancer?Īccording to the latest SEER database figures for Neuroendocrine Cancer, one reason for the 7 fold increase in incidence rates since the 1970s is all of those things above including better diagnostics. This is against a backdrop of better awareness, better screening in the big population cancers, and to a certain extent better diagnostic tools, all of which is leading to earlier diagnosis. Fortunately, more people are surviving than ever before. Let us know how this access is important for you.Cancer is a growth industry …literally! More people are being diagnosed than ever before. Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Here, we review the current state of probe-development from a translational viewpoint and make a case for a clinically viable, 18F-labeled alternative to the current standard Ga-DOTA-TATE. The clinical introduction of an 18F-labeled SSTR-imaging probe can help mitigate the shortcomings of the generator-based synthesis approach, but despite extensive research efforts, none of the proposed 18F-labeled SSAs has been translated past prospective first-in-humans studies so far. The synthesis of 68Ga-labeled SSAs from a 68Ge/ 68Ga-generator is straightforward and allows for a decentralized production, but there are economic and logistic difficulties associated with these approaches that warrant the search for a viable, generator-independent alternative. Driven by the demand for PET/CT imaging of NETs, a commercial kit for the production of Ga-DOTA-TATE (NETSPOT) was approved by the U.S. PET/CT imaging with SSAs such as Ga-DOTA-TATE, Ga-DOTA-TOC, and Ga-DOTA-NOC allows for NET staging with high accuracy and is used to qualify patients for RLT. On the diagnostics side, the field is currently dominated by 68Ga-labeled SSAs for the molecular imaging of NETs with positron emission tomography-computed tomography (PET/CT). With the Neuroendocrine Tumor Therapy (NETTER-1) phase 3 trial reporting encouraging results in the treatment of well-differentiated, metastatic midgut NETs, peptide radioligand therapy (RLT) with the 177Lu-labeled somatostatin analog (SSA) Lu-DOTA-TATE is now anticipated to become the standard of care. The development of theranostic pairs comprising somatostatin receptor (SSTR)-targeting nuclear imaging probes and therapeutic agents for the treatment of patients with neuroendocrine tumors (NETs) has been a driving force behind this development. The trend to inform personalized molecular radiotherapy with molecular imaging diagnostics, a concept referred to as theranostics, has transformed the field of nuclear medicine in recent years.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |